This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oragenics, Inc. (NYSE MKT: OGEN) (the “Company”) announced today that it has completed its previously announced underwritten public offering of 4,400,000 shares of common stock at a public offering price of $2.50 per share. The net proceeds to the company, after underwriting discounts and commissions and estimated offering expenses, were $9,847,500.
Griffin Securities was the sole underwriter for the offering.
The Company filed a registration statement on Form S-3, as well as a final prospectus supplement and accompanying prospectus, with the Securities and Exchange Commission. The final prospectus supplement and accompanying prospectus relating to the offering may be obtained by sending a request to Griffin Securities, Inc., by calling (212) 509-9500 or by mail at Griffin Securities, Inc. 17 State Street New York, NY 10004.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering.
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets. Oragenics has established exclusive worldwide channel collaborations for lantibiotics and probiotics, with Intrexon Corporation Inc., a leading synthetic biology company. The lantibiotics collaboration allows Oragenics access to Intrexon’s proprietary technologies to accelerate the development of much needed new antibiotics that will work against resistant strains of bacteria. The probiotics collaboration allows Oragenics access to Intrexon’s proprietary technologies to develop and commercialize probiotics, specifically the direct administration to humans of genetically engineered probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus, including, but not limited to, aphthous stomatitis and Behcet’s disease. Oragenics also develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in over 13 countries worldwide.